Accounts and other information Group Cash Flow Statement Year ended Year ended Year ended 31 December 2011 31 December 2010 31 December 2009 Notes $ million $ million $ million Cash ows from operating activities profit before taxation 848 895 670 Net interest payable 4 8 15 40 Depreciation, amortisation and impairment 297 273 298 Loss on disposal of property, plant and equipment and software 9 15 14 Share based payments expense 30 21 18 Share of results of associates 2 Decrease in retirement benefit obligations 44 31 2 Decrease Increase in inventories 40 21 17 Increase Decrease in trade and other receivables 47 100 46 Decrease Increase in trade and other payables and provisions 6 2 35 Cash generated from operations i ii 1,135 1,111 1,030 Interest received 4 32 Interest paid 12 20 43 Income taxes paid 285 235 270 Net cash inow from operating activities 842 859 719 Cash ows from investing activities 22 Acquisitions net of $2m of cash received in 2011 33 25 Cash received from Plus settlement 22 137 Capital expenditure 321 315 318 Proceeds on disposal of property, plant and equipment and software 8 Net cash used in investing activities 354 307 206 Cash ows from nancing activities Proceeds from issue of ordinary share capital 17 15 7 Treasury shares purchased 6 5 Proceeds of borrowings due within one year 21 78 17 Settlement of borrowings due within one year 21 330 66 Proceeds on borrowings due after one year 21 277 526 92 Settlement of borrowings due after one year 21 232 714 814 Proceeds from own shares 7 810 Settlement of currency swaps 21 1 3 12 Equity dividends paid 20 146 132 120 Net cash used in nancing activities 521 537 469 Net decrease increase in cash and cash equivalents 33 15 44 Cash and cash equivalents at beginning of year 21 195 174 122 Exchange adjustments 21 1 68 21 161 195 174 Cash and cash equivalents at end of year i Includes $20m 2010 $16m, 2009 $32m of outgoings on restructuring and rationalisation expenses.
ii Includes $1m 2010 $nil, 2009 $22m of acquisition related costs and $3m 2010 $5m, 2009 $5m unreimbursed by insurers relating to macrotextured knee revisions.
The Notes on pages 88 to 128 are an integral part of these accounts.
